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Disruption of the mouse Atm gene, whose human counterpart is consistently mutated in ataxia-telangiec-
tasia (A-T) patients, creates an A-T mouse model exhibiting most of the A-T-related systematic and cellular
defects. While ATM plays a major role in signaling the p53 response to DNA strand break damage, Atm2/2
p532/2 mice develop lymphomas earlier than Atm2/2 or p532/2 mice, indicating that mutations in these two
genes lead to synergy in tumorigenesis. The cell cycle G1/S checkpoint is abolished in Atm
2/2 p532/2 mouse
embryonic fibroblasts (MEFs) following g-irradiation, suggesting that the partial G1 cell cycle arrest in
Atm2/2 cells following g-irradiation is due to the residual p53 response in these cells. In addition, the Atm2/2
p212/2 MEFs are more severely defective in their cell cycle G1 arrest following g-irradiation than Atm
2/2 and
p212/2 MEFs. The Atm2/2 MEFs exhibit multiple cellular proliferative defects in culture, and an increased
constitutive level of p21 in these cells might account for these cellular proliferation defects. Consistent with this
notion, Atm2/2 p212/2 MEFs proliferate similarly to wild-type MEFs and exhibit no premature senescence.
These cellular proliferative defects are also rescued in Atm2/2 p532/2 MEFs and little p21 can be detected in
these cells, indicating that the abnormal p21 protein level in Atm2/2 cells is also p53 dependent and leads to
the cellular proliferative defects in these cells. However, the p21 mRNA level in Atm2/2 MEFs is lower than
that in Atm1/1 MEFs, suggesting that the higher level of constitutive p21 protein in Atm2/2 MEFs is likely due
to increased stability of the p21 protein.
Ataxia-telangiectasia (A-T) is an autosomally recessive hu-
man genetic disease characterized by pleiotropic defects in
multiple systems. Affected patients suffer from growth retar-
dation, neuronal degeneration in the cerebellum leading to
ataxia, dilated blood vessels in the eye and facial area, gonadal
defects, immunodeficiency, a high incidence of cancer, and
hypersensitivity to ionizing radiation (20). Cells derived from
A-T patients are defective in their checkpoint responses to
ionizing radiation and are hypersensitive to ionizing radiation
(22, 27). Following the induction of strand break damage in-
duced by ionizing radiation, normal cells arrest their cell cycle
at three cell cycle checkpoints: at the G1/S border, at S phase,
and at the G2/M border (12). However, all three cell cycle
checkpoints in A-T cells are defective in response to ionizing
radiation. The cell cycle checkpoint defects of A-T cells have
been suggested to account for the cellular hypersensitivity of
these cells to ionizing radiation (22, 27).
A gene consistently mutated in A-T patients, denoted ATM,
has been identified through linkage mapping and positional
cloning (9, 26). The ATM gene encodes a large kinase which is
similar to a family of kinases involved in DNA metabolism and
cell cycle checkpoint control in response to DNA damage (26,
34). While the ATM kinase family members contain a kinase
domain similar to that of phosphatidylinositol 3-kinase (PI-3
kinase), none of them have been shown to have any lipid
kinase activity (13). Instead, a number of ATM family mem-
bers, including FRAP, DNA-PK, and ATM, display protein
kinase activity (3, 4, 11, 16). In addition, immunofluorescence
studies using an anti-ATM antibody have shown that ATM is
ubiquitously expressed in all murine tissues and is mainly lo-
calized in the nucleus, consistent with the notion that ATM
may be involved in the detection of DNA strand break damage
and in the activation of cell cycle checkpoints following DNA
strand break damage (6).
To clarify the function of ATM and create a mouse model to
study the basis of the pleiotropic defects in A-T patients, we
disrupted the Atm gene in mice through homologous recom-
binations (33). Mice homozygous for this mutation express
most of the A-T phenotypes, including neural degeneration,
growth retardation, abolished germ cell development, immune
defects, and a high incidence of thymic lymphomas (19, 31).
Furthermore, primary cells derived from the Atm2/2 mice
displayed cellular defects characteristic of A-T, including hy-
persensitivity to g-irradiation and defective cell cycle G1/S and
S-phase checkpoint control following g-irradiation (3, 33). In
addition, Atm2/2 mouse embryonic fibroblasts (MEFs) exhibit
defective cellular proliferation, inefficient G1- to S-phase cell
cycle progression and premature senescence in culture (33).
Similar systematic and cellular defects have been reported in
two independently generated Atm2/2 mouse strains (1, 8).
Therefore, Atm plays important roles in both cellular re-
sponses to strand break damage and normal cellular growth.
p53 is required for the cell cycle G1 arrest following g-irra-
diation (18). The impaired p53 response to g-irradiation in
Atm2/2 cells could account for the defective cell cycle G1
arrest in these cells (15, 17, 33). In addition, the increased
constitutive level of p21CIP1/WAF1 observed in Atm2/2 MEFs
might account for the cellular proliferative defects observed in
these mutant cells because p21 is involved in the inhibition of
G1- to S-phase cell cycle progression (5, 7, 30). To test the roles
of the defective p53 response and the abnormal p21 protein
level in the cellular and developmental defects observed in
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Atm2/2 mice, Atm2/2 p212/2 and Atm2/2 p532/2 mice were
generated.
The majority of Atm2/2 p532/2 mice die embryonically. The
born double mutant mice are runted and develop lymphomas
sometimes of both B and T origin by 2 months of age, indicat-
ing a synergy of the Atm and p53 mutations in tumorigenesis
since Atm2/2 mice develop thymic lymphomas by 4 months of
age. Similar to p532/2 cells, Atm2/2 p532/2 cells are com-
pletely defective in their cell cycle G1 arrest following g-irra-
diation, indicating that the impaired but not abolished p53
response in Atm2/2 cells contributes to the partial cell cycle G1
arrest following g-irradiation in these cells (33). However, this
synergy in tumorigenesis is not observed in Atm2/2 p212/2
mice. The development of Atm2/2 p212/2 mice is grossly
similar to that of Atm2/2 mice. However, when compared with
wild-type and p212/2 MEFs, the Atm2/2 p212/2 MEFs pro-
liferate normally at both low and high passages, consistent with
the notion that the increased constitutive level of p21 in
Atm2/2 MEFs causes the cellular proliferation defects ob-
served in these cells. In addition, because little p21 is observed
in Atm2/2 p532/2 MEFs, the increased p21 protein level in
Atm2/2 MEFs is p53 dependent and likely due to a more
stable p21 protein, because the p21 mRNA level in Atm2/2
MEFs is lower instead of higher than that in Atm1/1 MEFs.
MATERIALS AND METHODS
Generation of Atm2/2 p212/2 and Atm2/2 p532/2 mice. The p212/2 and
p532/2 mice were described previously (5, 14). Because Atm2/2 mice are sterile
(31), the p212/2 mice were bred with Atm1/2 mice to generate Atm1/2 p211/2
mice, which were intercrossed to generate Atm1/2 p212/2 mice. The Atm1/2
p212/2 mice were then intercrossed to generate Atm2/2 p212/2 mice. A similar
breeding scheme was attempted to generate Atm2/2 p532/2 mice but attempts
to intercross Atm1/2 p532/2 mice have failed. So Atm1/2 p531/2 mice were
intercrossed instead to generate Atm2/2 p532/2 mice.
Flow cytometric analysis of thymocytes. Thymi were surgically removed from
mice and single-cell suspensions were prepared as previously described (31). For
two-color flow cytometric analysis, one-half million cells were silmutaneously
stained with phycoerythrin-conjugated anti-CD4 antibody and fluorescein iso-
thiocyanate (FITC)-conjugated anti-CD8 antibody. After being washed with
staining buffer (3% fetal bovine serum [FBS] in phosphate-buffered saline
[PBS]), stained cells were analyzed using a FACScan (Becton-Dickinson) and
CellQuest software. All antibodies were obtained from Pharmingen.
Generation and culture of MEFs. MEFs were derived from day 14 or day 16
embryos as previously described (33). The Atm2/2 p212/2 or Atm2/2 p532/2
MEFs were derived from embryos obtained through the intercrosses of Atm1/2
p212/2 mice or Atm1/2 p531/2 mice, respectively. MEFs were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum, 5 mM glutamine, 50 mM b-mecaptoethanol, 50 U of penicillin per ml,
and 50 U of streptomycin per ml at 37°C with 5% CO2.
g-Irradiation treatment of MEFs and cell cycle analysis. MEFs were synchro-
nized at the G0 phase of the cell cycle by culturing in medium supplemented with
0.1% FBS for 96 h as previously described (7). The G0-synchronized cells were
trypsinized and irradiated in suspension with a 137Cs g-ray source. Subsequently,
the irradiated and untreated MEFs were plated in 10-cm-diameter plates at a
density of 0.8 3 106 to 1 3 106 cells/plate in normal growth medium supple-
mented with 10 mM bromodeoxyuridine (BrdU). After 24 h of BrdU labeling,
cells were harvested, fixed in 70% ethanol, and stored at 220°C until analysis.
The analyses of DNA content and synthesis were performed as previously
described (33). DNA content was revealed by staining with propidium iodide,
and DNA synthesis was revealed by staining with FITC-conjugated anti-BrdU
antibody (Southern Biotech., Inc.). The stained cells were analyzed using a
FACScan and the CellQuest program as previously described (33).
Northern blot analysis. Total RNA was prepared from harvested MEFs with
Trizol reagent (Sigma) according to the manufacturer’s protocol. Total RNA (15
mg) was electrophoresed on a 17.5% formaldehyde-1% agarose gel and was
transferred to a nylon membrane (Amersham) as previously described (32). The
full-length mouse p21 cDNA was used as a probe to hybridize to the membrane
as previously described (21). To standardize the amount of RNA loaded into
each lane, the same filter was stripped and hybridized with a glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) probe as previously described (32). The
hybridized filter was sequentially exposed to both X-ray films and PhosphorIm-
ager screens. The amount of p21 and GAPDH mRNA in each sample was
quantitated with an ImageQuant program (Molecular Dynamics).
Assays for in vitro cellular proliferation and G1/S cell cycle progression.
Cellular proliferation assays were performed as previously described (7, 33).
Briefly, 105 MEFs were plated onto each 35-mm-diameter plate, and each day
after plating, MEFs from three plates of each genotype were trypsinized and
counted with a hematocytometer. To synchronize MEFs at G0, a subconfluent
culture was washed with PBS and placed in DMEM containing 0.1% FBS for
96 h (7). The synchronized MEFs were harvested and released into DMEM
supplemented with 10% FBS and 10 mM BrdU for 24 h. Cells in S phase were
analyzed using flow cytometry as described above.
Western blot analysis. Western blot analysis of p21 protein levels in MEFs was
performed as previously described (33). Protein extracts derived from 3 3 105
cells were loaded into each lane, separated by sodium dodecyl sulfate–12%
polyacrylamide gel electrophoresis, and transferred to nitrocellulose membranes
(Schleicher and Schuell). The filter was probed with a polyclonal rabbit anti-p21
antibody obtained from Santa Cruz Biochemicals, and then was incubated with
horseradish peroxidase-conjugated secondary antibody and developed with en-
hanced chemiluminescence (Amersham). To verify that an equivalent amount of
protein was loaded into each lane, the same filter was subsequently probed with
a polyclonal rabbit anti-tubulin antibody (ICN Biomedicals, Inc.) and developed
as described above.
RESULTS
Developmental phenotypes in Atm2/2 p532/2 and Atm2/2
p212/2 mice. Because p532/2 Atm1/2 mice are not healthy
and usually develop testicular sarcomas, attempts to use these
mice to generate Atm2/2 p532/2 mice have failed so far.
(Testicular sarcomas are also a common malignancy found in
the strain of p532/2 mice that we used [14].) Therefore,
Atm1/2 p531/2 mice were intercrossed to generate Atm2/2
p532/2 mice. While the predicted frequency of Atm2/2 p532/2
mice in the offspring of this intercross should be 1/16, only
about 2% of over 350 offspring genotyped were Atm2/2
p532/2 mice, suggesting that about 60% of these double mu-
tant mice die prenatally. In addition, the born Atm2/2 p532/2
mice are apparently runted at the weaning age and thus the
prevalence of growth retardation phenotypes is hard to judge.
To generate Atm2/2 p212/2 mice, Atm1/2 p212/2 mice
were generated and intercrossed. Consistent with the predicted
frequency of 1/4, about 25% of the offspring from the Atm1/2
p212/2 crosses were double mutant animals, indicating that
there is no prenatal death during the early development of the
double mutant mice (data not shown).
Atm2/2 mice exhibit several developmental defects, includ-
ing growth retardation and defective T-cell development (31).
While the Atm2/2 p532/2 mice are runted and appear un-
healthy by the weaning age, the Atm2/2 p212/2 mice are
healthy at this stage of development and were studied for this
spectrum of developmental defects. Similar to Atm2/2 mice
(31), the 1- to 2-month-old Atm2/2 p212/2 mice are also
growth retarded with a body weight about 79% 6 7% of that
of the p212/2 control mice (data derived from six sets of
Atm2/2 p212/2 and Atm1/1 p212/2 mice).
T-cell developments in Atm2/2 p212/2 mice were analyzed
using flow cytometry and cell counting. While the total number
of thymocytes in Atm2/2 mice is on average 40% 6 10% of
that of Atm1/1 control mice (33), the total number of thymo-
cytes in the Atm2/2 p532/2 and Atm2/2 p212/2 mice in this
study averaged 50% 6 5% and 52% 6 12%, respectively, of
those of p532/2 and p212/2 control mice (data derived from
four sets of Atm2/2 p532/2 and p532/2 control mice and seven
sets of 1- to 2-month-old Atm2/2 p212/2 and Atm1/1 p212/2
control mice). In addition, when determined by flow cytometry
for the expression of CD4 and CD8 surface markers, CD41
and CD81 single-positive mature thymocytes were still signif-
icantly reduced in the thymi of Atm2/2 p212/2 and Atm2/2
p532/2 mice compared to those of Atm1/1 p212/2 and
Atm1/1 p532/2 control mice, respectively (Fig. 1). Therefore,
the thymocyte differentiation from the CD41 CD81 stage to
the CD41 or CD81 stage is consistently defective in Atm2/2,
Atm2/2 p212/2, and Atm2/2 p532/2 mice.
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Lymphomas in Atm2/2 p532/2 and Atm2/2 p212/2 mice.
While Atm2/2 mice invariably develop thymic lymphomas by 4
months of age, seven Atm2/2 p532/2 mice developed thymic
and/or peripheral lymphomas by 2 months of age. When ana-
lyzed with flow cytometry, three of the seven lymphomas de-
rived from Atm2/2 p532/2 mice appear to have been com-
posed of two populations of tumor cells of different sizes (Fig.
2A). When the analysis was gated on these two populations of
tumor cells, the smaller tumor cells appeared to be mainly
composed of B2201 cells, which are also Thy-12 CD42, indi-
cating that they are phenotypically of B-cell origin (Fig. 2B and
data not shown). The larger tumor cells expressed some T-cell
markers, including CD4 and Thy-1, but were B2202, suggest-
ing that they were of T-cell origin (Fig. 2B and data not
shown). Therefore, the Atm2/2 p532/2 mice can develop lym-
phomas of both B- and T-cell origin.
Similar to Atm2/2 mice, Atm2/2 p212/2 mice invariably
develop thymic lymphomas by 5 months of age, and no other
malignancies have been detected in these animals at an ele-
vated frequency. In addition, similar to the thymic lymphoma
cells derived from Atm2/2 mice, the thymic lymphoma cells
observed in Atm2/2 p212/2 mice are mostly of CD41 CD81
immature T-cell origin (data not shown) (31).
Cell cycle G1 arrest following g-irradiation in Atm
2/2
p532/2 and Atm2/2 p212/2 MEFs. In response to g-irradia-
tion, Atm2/2 MEFs are partially defective in their cell cycle G1
arrest, presumably due to a greatly reduced and delayed p53
upregulation in response to g-irradiation (33). In addition, the
constitutively higher basal protein level of p21 in Atm2/2
MEFs might also affect the cell cycle G1 arrest of these cells in
response to g-irradiation (33). To test these possibilities, the
cell cycle G1 arrest following g-irradiation in Atm
2/2 p532/2
and Atm2/2 p212/2 MEFs was evaluated as previously de-
scribed (7). Briefly, MEFs synchronized at G0 by serum star-
vation were treated with 0 or 10 Gy of g irradiation and re-
leased into medium supplemented with 10% FBS and 10 mM
BrdU. After 24 h, the percentages of S-phase cells in the
irradiated and untreated MEFs were assayed with flow cytom-
etry as previously described (31) (Fig. 3A). Following g-irra-
diation, there is essentially no cell cycle G1 arrest in p53
2/2
and p532/2 Atm2/2 MEFs while there is more than 50%
reduction of S-phase cells in wild-type MEFs (Fig. 3B). In
addition, the Atm2/2 p212/2 MEFs are more severely defec-
tive in their cell cycle G1 arrest following g-irradiation than
p212/2 and Atm2/2 MEFs (Fig. 3B).
Growth properties of Atm2/2 p212/2 and Atm2/2 p532/2
MEFs. The Atm2/2 MEFs exhibit defects in cellular prolifer-
ation, including slower proliferation rate, lower saturation den-
sity, inefficient G1- to S-phase cell cycle progression, and pre-
mature senescence, possibly due to the increased basal level of
p21 in these mutant cells (33). Therefore, the cellular prolif-
eration of Atm2/2 p212/2 and Atm2/2 p532/2 MEFs were
examined as previously described (33). At earlier passages,
Atm2/2 p212/2, Atm2/2 p532/2, p212/2, and wild-type MEFs
proliferate similarly and reach similar saturation densities,
while as expected, Atm2/2 MEFs proliferate more slowly (Fig.
4A). In addition, Atm2/2 p212/2 and Atm2/2 p532/2 MEFs
are capable of proliferating at high passages (passage 6), while
Atm2/2 MEFs are senescent (data not shown) (26, 33).
The cell cycle G1- to S-phase progression was examined as
previously described (33). Atm1/1, Atm1/1 p212/2, Atm2/2
p212/2, Atm1/1 p532/2, and Atm2/2 p532/2 MEFs synchro-
nized at G0 through serum starvation were serum stimulated
for 24 h, and the percentages of cells in S phase were deter-
mined with flow cytometry. Similar percentages of S-phase
cells were detected in all the MEF samples tested (Fig. 4B).
Therefore, all the cellular proliferation defects tested in
FIG. 1. Flow cytometric analysis of T-cell development in 1- to 2-month-old Atm1/1, Atm2/2, Atm2/2 p532/2, Atm1/1 p212/2, and Atm2/2 p212/2 mice. Cells
residing in the lymphoid gate were analyzed and the percentages of total cells in a particular gate are indicated. Consistent data were obtained from two Atm2/2 p532/2
mice and seven sets of Atm1/1 p212/2 and Atm2/2 p212/2 mice.
FIG. 2. FACScan profile of lymphomas in Atm2/2 p532/2 mice. Peripheral
lymphomas derived from a 6-week-old Atm2/2 p532/2 mouse were analyzed for
cell size (A) and surface expression of pan-T-cell marker Thy-1 and pan-B-cell
marker B220 (B). The plot of the forward scatter (FSC) versus the sizing scatter
(SSC) indicates two populations of uniform lymphoma cells in the tumor, as
indicated by R1 and R2 gates.
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Atm2/2 MEFs are rescued in Atm2/2 p532/2 and Atm2/2
p212/2 MEFs.
p21 protein and mRNA levels in various MEFs. To test
whether the increased basal protein level of p21 in Atm2/2
mice is dependent on p53, the p21 protein level in Atm2/2
p532/2 MEFs was analyzed by Western blotting. As described
previously, a much higher level of p21 was detected in Atm2/2
MEFs than Atm1/1 MEFs (Fig. 5A) (31). However, little p21
protein was detected in both p532/2 and Atm2/2 p532/2
MEFs (Fig. 5A). As expected, no p21 could be detected in
Atm2/2 p212/2 and Atm1/1 p212/2 MEFs (Fig. 5A).
To test whether the increased level of p21 protein in Atm2/2
MEFs is due to a higher level of p21 mRNA in these cells, total
RNA was prepared from passage 3 Atm2/2 and Atm1/1 con-
trol MEFs and analyzed by Northern blotting using the full-
length mouse p21 cDNA as a probe (21). While the p21
mRNA could be easily identified in both Atm1/1 and Atm2/2
MEF samples, a lower p21 mRNA level was detected in the
Atm2/2 MEF samples compared to that of Atm1/1 MEF
controls derived from the same pregnant female, indicating
that the increased level of constitutive p21 protein in Atm2/2
MEFs is not due to the higher p21 mRNA level in these cells
(Fig. 5B). Consistent data were obtained from an additional
two sets of Atm1/1 and Atm2/2 MEFs (data not shown).
DISCUSSION
Atm2/2 cells show an impaired p53 upregulation in re-
sponse to g-irradiation and an increased level of p21, either or
both of which could be responsible for their cellular defects
and increased tumorigenesis. To study this issue, we generated
Atm2/2 p532/2 and Atm2/2 p212/2 mice and derived MEFs
from them. The cellular proliferative defects observed in
Atm2/2 MEFs are absent in Atm2/2 p212/2 and Atm2/2
p532/2 MEFs. In addition, the cell cycle G1 checkpoint re-
sponse to g-irradiation is more severely defective in Atm2/2
p532/2 and Atm2/2 p212/2 MEFs than in Atm2/2 MEFs.
While the developmental defects and tumorigenesis in the
Atm2/2 p212/2 mice are similar to those in Atm2/2 mice, the
majority of Atm2/2 p532/2 mice die prenatally and the sur-
viving Atm2/2 p532/2 mice develop tumors earlier than the
Atm2/2 and p532/2 mice, suggesting a cooperation of Atm
and p53 in mouse embryonic development as well as in tumor
suppression.
An increased p21 protein level can inhibit cell cycle G1/S
transition and is also correlated with cellular senescence (10,
23–25, 30). Therefore, an increased constitutive p21 protein
level in Atm2/2 MEFs could account for the cellular prolifer-
ative defects, including slower proliferation, inefficient cell cy-
cle G1/S progression, and premature senescence (33). Consis-
tent with this notion, none of the cellular proliferative defects
observed in Atm2/2 MEFs were evident in Atm2/2 p212/2
MEFs, indicating that the increased constitutive p21 level is
indeed responsible for the cellular proliferative defects ob-
served in Atm2/2 cells. In addition, the proliferative defects
observed in Atm2/2 MEFs are also rescued in Atm2/2 p532/2
MEFs, probably due to the fact that a minimum level of p21 is
expressed in any p532/2 MEFs. Thus, the p21 expression in
cycling Atm2/2 MEFs is apparently p53 dependent, just as it is
in wild-type cells. Since in normal-cycling MEFs, p53 is thought
to transcriptionally activate p21 mRNA expression through
binding to the two p53 binding sites in the p21 promoter
region, the regulation of p21 expression by p53 in Atm2/2
MEFs is most likely at the transcriptional level (21).
The increased p21 level in the Atm2/2 MEFs might be due
to either a higher basal activity of the p53-p21 pathway leading
to an increased level of p21 mRNA or a more stable p21
protein in the Atm2/2 MEFs. However, a lower level of p21
mRNA was detected in the Atm2/2 MEFs than in the Atm1/1
control MEFs, indicating that the higher level of constitutive
p21 protein in the Atm2/2 MEFs is not due to a higher p21
mRNA level in these cells but is likely due to the increased
stability of p21 protein in these cells. This finding is also con-
sistent with the notion that ATM might be involved in the
maintenance of the p53 protein level not only after excessive
DNA damage but also during normal cellular proliferation.
While the cellular proliferative defects in Atm2/2 cells are
rescued in Atm2/2 p212/2 cells, the growth retardation ob-
served in Atm2/2 mice is not rescued in the Atm2/2 p212/2
mice because these double mutant mice are still smaller than
their p212/2 control littermates. Therefore, the growth retar-
dation in Atm2/2 mice cannot be due solely to the cellular
proliferative defects in Atm2/2 cells. Instead, other potential
defects, such as the abnormal production of growth factors due
to the neural defects in Atm2/2 mice, might account for the
growth retardation in Atm2/2 mice (19). In addition, there is
FIG. 3. Cell cycle G1 arrest following g-irradiation in MEFs of various ge-
notypes. (A) Representative FACScan profile of untreated and irradiated
Atm1/1 p532/2 and Atm2/2 p532/2 MEFs. The 2N and 4N DNA contents were
revealed by propidium iodide (PI) staining, and DNA synthesis was revealed by
staining with FITC-conjugated anti-BrdU antibody. Cells residing in G0/G1, S,
and G2/M phases are indicated by boxes. The percentages of S-phase cells are
also indicated. (B) Quantitative analysis of the reduction of S-phase cells fol-
lowing g-irradiation in Atm1/1, Atm1/1 p212/2, Atm2/2 p212/2, Atm1/1
p532/2, and Atm2/2 p532/2 MEFs. Two independent experiments were per-
formed and in each experiment, three irradiated samples of MEFs of each
genotype (except in the case of Atm2/2 MEFs, for which one set of samples is
involved) and untreated controls were compared. Mean values with standard
derivations (indicated by error bars) are presented.
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a significant reduction of the total number of thymocytes in
Atm2/2 mice, possibly due to defective thymocyte prolifera-
tion or impaired V(D)J recombination or both (31). However,
in contrast to the findings obtained for the Atm2/2 p212/2 and
Atm2/2 p532/2 MEFs, there is no apparent rescue of thymus
cellularity in the Atm2/2 p212/2 and Atm2/2 p532/2 mice,
indicating that p53 and p21 are not involved in the thymus
hypoplasia in Atm2/2 mice. However, this does not rule out
the possibility that defective thymocyte proliferation contrib-
utes to the thymus hypoplasia in Atm2/2 mice.
The cell cycle G1 arrest following g-irradiation is abolished
in p532/2 MEFs but is partially defective in Atm2/2 MEFs (15,
17, 18, 33). Consistent with the notion that the cell cycle G1
arrest in response to g-irradiation is p53 dependent (18), the
p53 upregulation in response to g-irradiation in Atm2/2 cells
is greatly impaired and delayed (15, 17, 33). Therefore, our
findings that Atm2/2 p532/2 MEFs are completely deficient in
their cell cycle G1 arrest in response to g-irradiation indicate
that the residual p53 response to g-irradiation in Atm2/2 cells
contributes to the partial G1 cell cycle arrest in Atm
2/2 MEFs.
Thus, in response to DNA strand break damage, ATM plays a
major role in signaling the p53 upregulation but there exist
ATM-independent signaling pathways that can partially com-
pensate for this ATM activity.
While ATM plays a major role in signaling the p53 response
to g-irradiation, the Atm2/2 p532/2 mice develop lymphomas
earlier than Atm2/2 mice, indicating that mutations in these
two genes can cooperate in tumorigenesis. Two observations
could account for this synergy in tumorigenesis. First, the cell
cycle checkpoint defects occurring in response to DNA dam-
age induced by g-irradiation are more severe in Atm2/2
p532/2 cells than in Atm2/2 cells. Secondly, the p53-depen-
dent apoptosis of thymocytes in response to g-irradiation is
only partially defective in Atm2/2 thymocytes but is completely
abolished in Atm2/2 p532/2 cells (29, 33). In addition, ATM
signals the upregulation of p53 only in response to DNA strand
break damage but is not involved in such signaling in the
cellular responses to DNA damage induced by UV or base
mismatch (33, 33a). Therefore, while only the cellular response
to DNA strand break damage is defective in Atm2/2 cells,
cellular responses to multiple forms of DNA damage and other
cellular stresses are defective in Atm2/2 p532/2 cells, thus
providing the potential basis for the synergy of tumorigenesis
FIG. 4. In vitro cellular proliferation and G1/S-phase cell cycle progression following serum stimulation of MEFs of various genotypes. (A) Proliferation curves and
saturation densities of Atm1/1, Atm2/2, Atm1/1 p212/2, Atm2/2 p212/2, Atm1/1 p532/2, and Atm2/2 p532/2 MEFs at passage 3. The cell numbers represent the
averages of three plates counted at each time point. (B) Quantitative analysis of the percentage of S-phase cells after serum stimulation for 24 h of G0-synchronized
Atm1/1, Atm1/1 p212/2, Atm2/2 p212/2, Atm1/1 p532/2, and Atm2/2 p532/2 MEFs. The BrdU-labeled MEFs were analyzed with flow cytometry, and the S-phase
cells were revealed by staining with anti-BrdU antibody. Three independent experiments were performed and the mean values with standard derivations (indicated by
error bars) are presented.
FIG. 5. p21 protein and mRNA levels in MEFs of various genotypes. (A) p21
protein levels in Atm1/1, Atm2/2, Atm1/1 p532/2, Atm2/2 p532/2, Atm1/1
p212/2, and Atm2/2 p212/2 MEFs. Both the short exposure and the long
exposure of the same Western blot are presented. The genotypes are shown at
the top. p21 and the b-tubulin are indicated by arrows. (B) p21 mRNA levels in
Atm2/2 and Atm1/1 control MEFs. The p21 mRNA and loading control
GAPDH are indicated by arrows. The genotypes are indicated at the top. The
levels of p21 and GAPDH mRNA in each sample were quantitated using an
ImageQuant program with a PhosphorImager (Molecular Dynamics). After the
p21 mRNA level of each sample was standardized with its GAPDH mRNA level,
the percentile ratio of the p21 mRNA level in Atm2/2 MEFs versus that in
Atm1/1 MEF controls was determined and is indicated at the bottom.
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in Atm2/2 p532/2 mice. The Atm2/2 p532/2 mice also de-
velop lymphomas earlier than p532/2 mice (14). Therefore,
other defective but p53-independent cellular responses to
strand break damage in Atm2/2 cells, such as the defective
S-phase cell cycle checkpoint which occurs in response to
strand break damage, can account for the earlier onset of
tumors in Atm2/2 p532/2 mice (3).
An independently generated Atm2/2 p532/2 mouse line was
reported while this paper was in preparation (29). The findings
for our Atm2/2 p532/2 mice are in general agreement with
those for the reported mouse line. While this paper was being
reviewed, two reports described the meiosis, tumorigenesis,
and apoptosis responses in two independently generated
Atm2/2 p212/2 mouse lines (2, 28).
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